CD163 and classic Hodgkin lymphoma: Many studies have found that CD68+ CD163+ M2-like TAMs are associated with poor clinical outcomes in patients with cHL [20,21,36,50], whereas others have not found such an association and have highlighted problems arising from technical heterogeneity [36,69].